Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:CARM

Carisma Therapeutics Earnings Date & Estimates

Carisma Therapeutics logo
$0.0005 0.00 (0.00%)
As of 10/8/2026 12:25 PM Eastern

Carisma Therapeutics is expected to report earnings on Thursday, November 5, 2026.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Carisma Therapeutics

Carisma Therapeutics is expected to post earnings of -$0.12 per share on revenue of $4.66 million. In the same quarter a year earlier Carisma Therapeutics reported $1.07 per share on revenue of $45.25 million. Carisma Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Expected Revenue
$4.66 million
Prior-Year EPS
$1.07
Prior-Year Revenue
$45.25 million
Expected EPS Growth
-111.6%
Expected Revenue Growth
-89.7%

Recent Track Record

Last Reported
Q3 2025
Last Quarter EPS
$1.07
Last Quarter Revenue
$45.25 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Carisma Therapeutics Earnings FAQ

Carisma Therapeutics (NASDAQ:CARM) is estimated to report earnings on Thursday, November 5, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Carisma Therapeutics to post earnings of -$0.12 per share for the quarter.

The consensus revenue estimate for Carisma Therapeutics is $4.66 million for the quarter.

Carisma Therapeutics Earnings Headlines

Carmila: 2025 Annual Results
February 18, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260218091340/en/Carmila-2025-Annual-Results/
Carisma Therapeutics announces Nasdaq delisting, SEC deregistration
December 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/carisma-therapeutics-announces-nasdaq-delisting-sec-deregistration/ar-AA1RNAg1
The Executive Order That Quietly Changed What Your Dollar Means
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
 |  Reagan Gold Group (Ad)
Carisma Announces Delisting from Nasdaq and SEC Deregistration
December 5, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/carisma-announces-delisting-from-nasdaq-and-sec-deregistration-302634179.html
Carisma Therapeutics Announces Executive Terminations and Wind-Down
October 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/carisma-therapeutics-announces-executive-terminations-and-wind-down/ar-AA1Oy1kT
Carisma Therapeutics stock plunges after Nasdaq delisting notice
October 10, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/carisma-therapeutics-stock-plunges-after-nasdaq-delisting-notice-93CH-4281908
See More Carisma Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email.

About Carisma Therapeutics

Carisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company focused on developing engineered macrophage and monocyte therapies for cancer and other serious diseases. Its approach is designed to harness the natural ability of these immune cells to locate and interact with disease sites while enhancing their ability to recognize and attack abnormal cells.

The company’s technology platform uses genetic engineering to create targeted cell therapies, including chimeric antigen receptor macrophage (CAR-M) candidates. Carisma’s programs are intended to address tumors that may be difficult for conventional immune-cell therapies to reach or treat, including solid tumors. Its lead programs have focused on HER2-targeted therapies, such as CT-0525, an investigational CAR-monocyte therapy being evaluated in clinical development.

Carisma Therapeutics was founded through research associated with the University of Pennsylvania and has established operations in Philadelphia. The company became publicly traded on the Nasdaq under the symbol CARM in 2023. Its leadership has included Steven Kelly as chief executive officer. Carisma’s research and development activities are primarily focused on advancing its macrophage-based immunotherapy platform and clinical pipeline.

View Carisma Therapeutics Profile
Earnings Tools